Clinical trials: Dementia Disorders
Healthy
Study Evaluating the Safety and Pharmacokinetics of a Single Dose of GSI-953
The purpose of the protocol is to assess the initial pharmacokinetic (PK) profile of a single oral dose of GSI-953 to healthy male Japanese subjects and healthy elderly male Japanese subjects.
- Trial name
- NCT00441987
- Testing
- GSI-953
- Where
- Japan
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Agitation,Psychomotor, Bipolar I Disorder
Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)
In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform…
- Conditions
- Agitation,Psychomotor, Bipolar I Disorder, Bipolar II Disorder, Schizophrenia
- Trial name
- NCT05658510
- Testing
- BXCL501
- Where
- 24 sites in United States
- Volunteers
- 452 people
- Sponsor
- BioXcel Therapeutics Inc
Psychosis Associated With Alzheimer's Disease
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated…
- Trial name
- NCT06887192
- Testing
- ML-007C-MA
- Where
- 62 sites in United States, Argentina and 13 more
- Volunteers
- 300 people
- Sponsor
- MapLight Therapeutics
Cognitive Impairment
A Study to Evaluate the Effectiveness of VIZAMYL™ Reader Training Programme in Europe
This is a study to determine the effectiveness of the VIZAMYL™ reader training programme in clinical practice in Europe
- Trial name
- NCT04773015
- Where
- 10 sites in Austria, Finland and 3 more
- Volunteers
- 227 people
- Sponsor
- GE Healthcare
Parkinson Disease
A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
This study will evaluate the safety, tolerability, and potential effects on cognition of GRF6021, a plasma-derived product, administered as an intravenous (IV) infusion, to subjects with Parkinson's disease and cognitive…
- Trial name
- NCT03713957
- Testing
- GRF6021
- Where
- 29 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Alkahest, Inc.
Mild Cognitive Impairment, Alzheimer's Disease
Aftobetin-HCl and Fluorescence Detection Measured by Sapphire II to Determine the Number and Timing of Administrations
This is an open-label study to evaluate Aftobetin-HCl and florescence detection as measured by the Sapphire II device. Performance of Part I of the study has been completed (15 subjects received a single administration of…
- Trial name
- NCT02928211
- Testing
- Sapphire II, Aftobetin-HCl, Positron Emission Tomography
- Where
- United States
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Cognoptix, Inc.
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Alzheimer's Disease
Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074
To evaluate the safety and tolerability of ascending oral doses of CHF 5074 administered once per day for up to 12 weeks to patients with mild cognitive impairment.
- Trial name
- CT04 (NCT01303744)
- Testing
- CHF 5074 1x, CHF 5074 2x, CHF 5074 3x
- Where
- 9 sites in United States, Italy
- Volunteers
- 96 people
- Sponsor
- CERESPIR
Alzheimer's Disease
Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease
The purpose of this study is to determine whether ORM-12741 is safe and effective in the treatment of Alzheimer's disease.
- Trial name
- ALPO (NCT01324518)
- Testing
- ORM-12741
- Where
- Finland
- Volunteers
- 100 people
- Sponsor
- Orion Corporation, Orion Pharma
Mild Cognitive Impairment, Alzheimer's Disease
A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits
REINVENT is a non-interventional, multi-center, research network-based cross-over study evaluating the potential utility of a telehealth platform in improving the efficiency of clinical trials.
- Trial name
- REINVENT (NCT02778438)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Quintiles, Inc.
Dementia, Alzheimer Disease
Treatment of Severe Alzheimer's Disease: Evaluation of Efficacy and Safety of Galantamine Hydrobromide in a Controlled Study
The purpose of this study is to assess the effectiveness and safety of galantamine hydrobromide treatment in patients with severe Alzheimer's disease.
- Trial name
- NCT00216593
- Testing
- galantamine hydrobromide
- Volunteers
- 415 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Parkinson's Disease Dementia (PDD)
SYN120 Study to Evaluate Its Safety, Tolerability and Efficacy in Parkinson's Disease Dementia (SYNAPSE)
The purpose of this study placebo-controlled, randomized, double-blind study is to assess the safety and efficacy of SYN120 in patients with Parkinson's disease dementia (PDD) already treated with a stable dose of a…
- Trial name
- SYNAPSE (NCT02258152)
- Testing
- SYN120
- Where
- 20 sites in United States
- Volunteers
- 82 people
- Sponsor
- Biotie Therapies Inc.
Alzheimer Disease, Neurofibrillary Tangle
Analysis of 18F-XTR006 PET Imaging in Cognitively Normal Subjects, and Patients With MCI and AD
The goal of this clinical trial is to evaluate the efficacy and safety of XTR006 injection PET visual reading in detecting brain neurofibrillary tangles (NFTs) in elderly subjects with Mild Cognitive Impairment (MCI), Alzheimer's…
- Trial name
- NCT07115238
- Testing
- XTR006
- Where
- China
- Volunteers
- 354 people, healthy volunteers welcome
- Sponsor
- Sinotau Pharmaceutical Group
Alzheimer's Disease
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC for cognitive impairment in Alzheimer's Disease
- Trial name
- MINDSET 1 (NCT06976216)
- Testing
- KarXT, KarX-EC
- Where
- 119 sites in United States, Argentina and 17 more
- Volunteers
- 586 people
- Sponsor
- Bristol-Myers Squibb
Huntington Disease, Huntington's Dementia
Prospective Single-Timepoint Huntington's Disease Biospecimen Collection Study
OBJECTIVES: The primary study objective is to collect blood from participants with Huntington's Disease in order to validate a CE marked Cytosine, Adenine, Guanine (CAG) assay for use in future studies for Huntington's Disease.
- Conditions
- Huntington Disease, Huntington's Dementia, Huntington Disease, Late Onset, Huntington; Dementia (Etiology)
- Trial name
- SAN-09611 (NCT05773196)
- Testing
- Biospecimen Collection
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Sanguine Biosciences
Alzheimer's Disease
Study to Evaluate Safety, Tolerability and Immunogenicity of Vaccine (UB 311) in Subjects With Alzheimer's Disease
The purpose of this Phase I study is to determine whether the vaccine (UB 311), targeting the amyloid beta peptide (N-terminal amino acids, 1-14), is safe and immunogenic in patients diagnosed with mild or moderate Alzheimer's…
- Trial name
- NCT00965588
- Testing
- UB 311
- Where
- 2 sites in Taiwan
- Volunteers
- 19 people
- Sponsor
- United Biomedical
Alzheimer Disease
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
This is a Phase 2b, Randomized, Double-blind, Placebo-controlled, multiple dose study of PTI-125 in mild-to-moderate Alzheimer's disease patients.
- Trial name
- NCT04079803
- Testing
- Simufilam 100 mg tablet, Simufilam 50 mg oral tablet
- Where
- 9 sites in United States
- Volunteers
- 64 people
- Sponsor
- Cassava Sciences, Inc.
Alzheimer Disease
Study Evaluating the Safety, Tolerability, and Efficacy of Lecozotan SR in Outpatients With Alzheimer's Disease
The purpose of the study is to determine the safety, tolerability, and efficacy of 3 doses of lecozotan in combination with a cholinesterase inhibitor in patients with mild to moderate Alzheimer's disease (AD).
- Trial name
- NCT00277810
- Testing
- lecozotan SR (SRA-333)
- Where
- 83 sites in United States, Argentina and 9 more
- Volunteers
- 250 people
- Sponsor
- Pfizer
Huntington Disease
Effect of PBT2 in Patients With Early to Mid Stage Huntington Disease
Huntington disease (HD) is an inherited neurodegenerative disease which affects over 30,000 people in both the United States and Australia.
- Trial name
- Reach2HD (NCT01590888)
- Testing
- PBT2
- Where
- 19 sites in United States, Australia
- Volunteers
- 109 people
- Sponsor
- Prana Biotechnology Limited
Huntington Disease
Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease
The goal of this clinical trial is to test if the drug SKY-0515, an oral medication, can lower harmful proteins linked to Huntington's Disease (HD) and improve the symptoms of participants with HD.
- Trial name
- FALCON-HD (NCT07378644)
- Testing
- SKY-0515
- Where
- 31 sites in United States, Argentina and 8 more
- Volunteers
- 400 people
- Sponsor
- Skyhawk Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.